Novel therapeutic target for diabetic kidney disease through ...
Seven weeks of celastrol (1.5 mg/kg/day) treatment significantly ameliorated DKD. Celastrol improves kidney functions. Moreover, celastrol treatment demonstrated potent antioxidant effect.
Novel therapeutic target for diabetic kidney disease through ...
Dec 19, 2024 · Seven weeks of celastrol (1.5 mg/kg/day) treatment significantly ameliorated DKD. Celastrol improves kidney functions. Moreover, celastrol treatment demonstrated potent …
Molecular Therapeutics for Diabetic Kidney Disease: An Update
Sep 19, 2024 · Celastrol, an inhibitor of NF-κB, can improve insulin resistance and play an anti-inflammatory role, making it a new useful method for treating DKD . In addition, the NF-κB …
Study of molecular mechanisms underlying the medicinal plant ...
Celastrol, a quinone methide triterpene, extracted from Tripterygium wilfordii has been shown to possess various pharmacological properties, including anti-inflammatory, anti-autoimmune, …
Macrophage inflammatory protein-1β as a novel ... - ScienceDirect
May 1, 2023 · Pre-clinical studies have shown that different interventions targeting inflammation modulation can successfully attenuate DKD severity. Celastrol has been shown to protect …
Piao LUO | Medical Professional | Southern Medical University ...
Celastrol, a natural bioactive triterpenoid extracted from Tripterygium wilfordii, shows effective anti-fibrotic and anti-inflammatory activities in multiple hepatic diseases.
Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and ...
Apr 26, 2013 · We investigated the effects of the NF-κB inhibitor celastrol in db/db mice. The treatment with celastrol for 2 months significantly lowered fasting plasma glucose (FPG), …
Celastrol antagonizes high glucose-evoked podocyte injury, …
Dec 1, 2018 · In this review, we briefly summarize underlying mechanisms of autophagy dysregulation in DKD, including AMP-activated protein kinase (AMPK), the mechanistic target …
Celastrol in metabolic diseases: Progress and application prospects
May 1, 2021 · Celastrol-regulated cellular signaling pathways leading to insulin resistance reversal in treating diabetes. Celastrol reversed insulin resistance by disrupting PA and MD2 …
Targeting endothelin signaling in podocyte injury and diabetic ...
Sep 20, 2024 · This article aims to elucidate the role of endothelin in podocyte injury in DN-DKD, highlighting its potential as a therapeutic target to arrest or reverse disease progression. …